BiotechTubeBiotechTube
Home/Agomab Therapeutics/Paul van der Horst
PV

Paul van der Horst

Chief Business Officer

Agomab Therapeutics

Therapeutic Areas

ImmunologyInflammatory DiseasesFibrosis

Agomab Therapeutics Pipeline

DrugIndicationPhase
Ontunisertib (AGMB-129)Fibrostenotic Crohn's DiseasePhase 1
AGMB-447Not SpecifiedNot Disclosed
AGMB-101Not SpecifiedNot Disclosed

Leadership Team at Agomab Therapeutics

TK
Tim Knotnerus
Chief Executive Officer
PW
Philippe Wiesel
Chief Medical Officer
AS
Andrea Sáez
Chief Development Officer
PK
Pierre Kemula
Chief Financial Officer
EL
Ellen Lefever
General Counsel
DE
David Epstein
Chairman of the Board
AJ
Angelika Jahreis
Non-Executive Director
CB
Colin Bond
Non-Executive Director and Chairman of the Audit Committee
FV
Felice Verduyn-van Weegen
Non-Executive Director (Representing EQT Life Sciences)
OH
Ohad Hammer
Non-Executive Director (Representing Pontifax)
View full Agomab Therapeutics profile